Aclaris Therapeutics, Inc. business relationships
Companies named in Aclaris Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Aclaris Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Aclaris Therapeutics, Inc.’s annual report 2
“...July 2024, we entered into a royalty purchase agreement with OMERS pursuant to which we sold to OMERS a portion of our future royalty payments and the remaining anniversary milestones associated with the license to Lilly (see "-Royalty Purchase Agreement with OCM IP Healthcare Portfolio LP" above).” SEC filing
“Under the license agreement, Lilly has paid us upfront, anniversary, regulatory and commercial milestone payments.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.